STAT+: Capsida says it still doesn’t know what caused gene therapy death
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Capsida Biotherapeutics said it still has no explanation for the September death of a child in its CAP‑002 gene‑therapy trial.
- Capsida Biotherapeutics reports the hospital conducting the trial has refused to share autopsy tissue samples, blocking its scientists from pinpointing the cause.
- CAP-002 is a first‑in‑class brain‑penetrating gene therapy designed to cross the blood‑brain barrier, part of a surge in viral‑vector treatments for rare and neurodegenerative diseases.
Why it matters: Capsida Biotherapeutics loses crucial data needed to explain the fatal outcome, delaying CAP‑002’s progress and shaking investor confidence, while families and the broader gene‑therapy field suffer from reduced safety transparency.
Ask SkimNews
